IL210681A0 - Signatures and pcdeterminants associated with prostate cancer and methods of use thereof - Google Patents

Signatures and pcdeterminants associated with prostate cancer and methods of use thereof

Info

Publication number
IL210681A0
IL210681A0 IL210681A IL21068111A IL210681A0 IL 210681 A0 IL210681 A0 IL 210681A0 IL 210681 A IL210681 A IL 210681A IL 21068111 A IL21068111 A IL 21068111A IL 210681 A0 IL210681 A0 IL 210681A0
Authority
IL
Israel
Prior art keywords
pcdeterminants
signatures
methods
prostate cancer
prostate
Prior art date
Application number
IL210681A
Other languages
English (en)
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of IL210681A0 publication Critical patent/IL210681A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
IL210681A 2008-07-16 2011-01-16 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof IL210681A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8128608P 2008-07-16 2008-07-16
PCT/US2009/050885 WO2010009337A2 (en) 2008-07-16 2009-07-16 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof

Publications (1)

Publication Number Publication Date
IL210681A0 true IL210681A0 (en) 2011-03-31

Family

ID=41551019

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210681A IL210681A0 (en) 2008-07-16 2011-01-16 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof

Country Status (14)

Country Link
US (3) US20110265197A1 (https=)
EP (1) EP2318543A2 (https=)
JP (1) JP2011528442A (https=)
KR (1) KR20110052627A (https=)
CN (1) CN102159727A (https=)
AU (1) AU2009270851A1 (https=)
BR (1) BRPI0916229A2 (https=)
CA (1) CA2730614A1 (https=)
IL (1) IL210681A0 (https=)
MX (1) MX2011000451A (https=)
NZ (1) NZ590851A (https=)
RU (1) RU2011105627A (https=)
WO (1) WO2010009337A2 (https=)
ZA (1) ZA201101132B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US20140030255A1 (en) * 2010-11-03 2014-01-30 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
US9458510B2 (en) 2011-06-27 2016-10-04 Mietamark Genetics, Inc. Signatures and determinants associated with prostate cancer progression and methods of use thereof
WO2013031757A1 (ja) * 2011-08-29 2013-03-07 東レ株式会社 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
WO2013163134A2 (en) * 2012-04-23 2013-10-31 The Trustees Of Columbia University In The City Of New York Biomolecular events in cancer revealed by attractor metagenes
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US20140011685A1 (en) * 2012-07-03 2014-01-09 Yixin Wang Genomic diagnostics using circulating endothelial cells
AU2013342273A1 (en) * 2012-11-09 2015-05-21 Dana-Farber Cancer Institute, Inc. Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
KR101456683B1 (ko) * 2013-01-04 2014-11-06 서울대학교산학협력단 폐암 진단용 마커
HK1216765A1 (zh) 2013-03-14 2016-12-02 奥特拉西斯公司 使用所测分析物改进疾病诊断的方法
WO2014152443A2 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Texas System Single-cell analysis as a sensitive and specific method for early prostate cancer detection
CN103602720A (zh) * 2013-06-24 2014-02-26 复旦大学附属肿瘤医院 前列腺癌基因标记物在标记前列腺癌复发和转移中的用途及方法
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
AU2014375206B2 (en) * 2014-01-03 2021-09-30 Innosign B.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression.
BR112016017132B1 (pt) 2014-01-28 2024-01-30 Quest Diagnostics Investments Incorporated Métodos para identificar uma zona de célula tipo tronco de câncer, uma zona de transição de adenoma-adenocarcinoma, um tumor de cólon, células-tronco de câncer, um indivíduo com câncer colorretal provável de responder favoravelmente ao tratamento com uma terapia alvejada pela via nf-kb, um indivíduo com perda genômica de 18q/smad4 e de 10q/pten, para diagnosticar um indivíduo com alto grau de adenoma de cólon e adenocarcinoma inicial, e para determinar a probabilidade de um tumor de cólon em um indivíduo passar por uma transformação invasiva se deixado sem tratamento e a probabilidade de um indivíduo com câncer colorretal (crc) responder favoravelmente ao tratamento com uma terapia alvejada pela via tgf-beta, e, kit para identificar uma região de transição de (...).
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017079571A1 (en) 2015-11-05 2017-05-11 Arphion Diagnostics Process for the indentication of patients at risk for oscc
US11079745B2 (en) * 2015-11-25 2021-08-03 Lawrence Livermore National Security, Llc Rapid closed-loop control based on machine learning
RU2018127709A (ru) 2016-01-22 2020-02-25 Отрэйсис, Инк. Системы и способы улучшения диагностики заболеваний
KR101881874B1 (ko) * 2016-04-29 2018-07-26 한국수력원자력 주식회사 저선량 방사선 조사에 의한 암화 예방 방법
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer
EP3507360A4 (en) * 2016-08-30 2020-07-29 Beth Israel Deaconess Medical Center Inc. COMPOSITIONS AND TREATMENT METHODS FOR TUMOR SUPPRESSOR-DEFICIENT CANCER
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
CA2984267A1 (en) * 2016-11-01 2018-05-01 Medarchon, Inc. Patient handoff device, system and predictive method
EP4001437A1 (en) * 2016-11-07 2022-05-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for selecting therapy for a cancer patient
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019213133A1 (en) * 2018-04-30 2019-11-07 City Of Hope Cancer detection and ablation system and method
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
JP6888123B2 (ja) * 2018-10-15 2021-06-16 イルミナ インコーポレイテッド 深層畳み込みニューラルネットワークを事前訓練するための深層学習ベースの技術
CA3126432A1 (en) * 2019-02-01 2020-08-06 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer
WO2020163581A1 (en) 2019-02-06 2020-08-13 Berg Llc Markers for the diagnosis of biochemical recurrence in prostate cancer
WO2021062261A1 (en) * 2019-09-25 2021-04-01 The Trustees Of Columbia University In The City Of New York Prognostic markers of metastatic cancer
KR102380529B1 (ko) * 2020-04-29 2022-03-31 인제대학교 산학협력단 전이성 전립선 암의 진단 및 예후 예측을 위한 혈중종양세포 기반 바이오 마커 조성물
US12271832B2 (en) * 2021-02-12 2025-04-08 Tempus Ai, Inc. Artificial intelligence engine for directed hypothesis generation and ranking
WO2026078234A1 (en) * 2024-10-10 2026-04-16 Consiglio Nazionale Delle Ricerche Prognostic signature for prostate cancer classification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7526387B2 (en) * 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2006086345A2 (en) * 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
CN101454331A (zh) * 2006-03-24 2009-06-10 菲诺梅诺米发现公司 有效用于诊断前列腺癌的生物标记，及其方法

Also Published As

Publication number Publication date
EP2318543A2 (en) 2011-05-11
US20110265197A1 (en) 2011-10-27
JP2011528442A (ja) 2011-11-17
US20140235479A1 (en) 2014-08-21
AU2009270851A1 (en) 2010-01-21
ZA201101132B (en) 2012-07-25
MX2011000451A (es) 2011-10-12
WO2010009337A2 (en) 2010-01-21
WO2010009337A3 (en) 2010-07-22
KR20110052627A (ko) 2011-05-18
CN102159727A (zh) 2011-08-17
WO2010009337A9 (en) 2010-03-04
NZ590851A (en) 2012-08-31
BRPI0916229A2 (pt) 2015-11-03
RU2011105627A (ru) 2012-08-27
US20170299594A1 (en) 2017-10-19
CA2730614A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
IL210681A0 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
IL269454B (en) Qualitative losses and their uses
GB2478441B (en) Lung cancer biomarkers and uses thereof
IL219992A0 (en) Combination therapy for treating cancer and dianostic assays for use therein
IL209754A0 (en) Diazacarbazoles and methods of use
ZA201003625B (en) 5-anilinoimidazopyridines and methods of use
IL223295A0 (en) Lung cancer biomarkers and uses thereof
EP2564200B8 (en) Cancer biomarkers and methods of use thereof
GB0819280D0 (en) Imgaing and radiotherapy methods
IL206125A0 (en) Azaindolizines and methods of use
IL209548A0 (en) Diazacarbazoles and methods of use
IL207212A0 (en) 4-pyridinone compounds and their use for cancer
ZA200906782B (en) Methods of activating IRS-1 and AKT
IL214757A0 (en) Compositions and methods to prevent and/or treat cancer with pa-card
EP2379098A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING CANCER WITH CUPREDOXINS
IL213657A0 (en) Compositions and methods to prevent cancer with cupredoxins
SG10201701286YA (en) Cancer detection methods and techniques
ZA201202657B (en) Use of the sparc microenvironment signature in the treatment of cancer
GB0813352D0 (en) Cancer treatment and test
IL211752A0 (en) Antibody combinations and use of same for treating cancer
GB0816523D0 (en) Methods and uses
AU2008906236A0 (en) Prostate Cancer Treatment Rectal Probe
HK1180315A (en) Kinase inhibitors and their use in treating cancer